Minimal transmission in an influenza A (H3N2) human challenge-transmission model within a controlled exposure environment.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
07 2020
Historique:
received: 28 02 2020
accepted: 14 06 2020
revised: 29 07 2020
pubmed: 14 7 2020
medline: 25 8 2020
entrez: 14 7 2020
Statut: epublish

Résumé

Uncertainty about the importance of influenza transmission by airborne droplet nuclei generates controversy for infection control. Human challenge-transmission studies have been supported as the most promising approach to fill this knowledge gap. Healthy, seronegative volunteer 'Donors' (n = 52) were randomly selected for intranasal challenge with influenza A/Wisconsin/67/2005 (H3N2). 'Recipients' randomized to Intervention (IR, n = 40) or Control (CR, n = 35) groups were exposed to Donors for four days. IRs wore face shields and hand sanitized frequently to limit large droplet and contact transmission. One transmitted infection was confirmed by serology in a CR, yielding a secondary attack rate of 2.9% among CR, 0% in IR (p = 0.47 for group difference), and 1.3% overall, significantly less than 16% (p<0.001) expected based on a proof-of-concept study secondary attack rate and considering that there were twice as many Donors and days of exposure. The main difference between these studies was mechanical building ventilation in the follow-on study, suggesting a possible role for aerosols.

Identifiants

pubmed: 32658939
doi: 10.1371/journal.ppat.1008704
pii: PPATHOGENS-D-20-00335
pmc: PMC7390452
doi:

Substances chimiques

Aerosols 0

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1008704

Subventions

Organisme : NCIRD CDC HHS
ID : U01 IP000497
Pays : United States

Déclaration de conflit d'intérêts

I have read the journal's policy and the authors of this manuscript have the following competing interests: JSN-V-T and BK declare previous consultancy fees from H-Vivo plc, unrelated to the current work. JSN-V-T is currently seconded to the Department of Health and Social Care (DHSC), England; the views expressed in this paper are not necessarily those of DHSC. RLW, AG and AM are employees of H-Vivo plc each of whom hold shares and /or share options in the company.

Références

J Infect Dis. 2018 Jul 24;218(5):739-747
pubmed: 29878137
J R Soc Interface. 2009 Dec 6;6 Suppl 6:S783-90
pubmed: 19773292
Proc Soc Exp Biol Med. 1966 Jul;122(3):800-4
pubmed: 5918954
Aerosol Sci Technol. 2013 Jan 1;47(4):444-451
pubmed: 23418400
mBio. 2018 Jan 23;9(1):
pubmed: 29362240
Am Rev Respir Dis. 1963 Sep;88:SUPPL 394-403
pubmed: 14064954
PLoS One. 2012;7(10):e46789
pubmed: 23056454
Nat Commun. 2013;4:1935
pubmed: 23736803
J Immunol. 1946 Feb;52:145-65
pubmed: 21018818
Front Cell Infect Microbiol. 2012 Nov 29;2:150
pubmed: 23226686
Influenza Other Respir Viruses. 2013 Sep;7 Suppl 2:42-51
pubmed: 24034483
PLoS Pathog. 2007 Oct 19;3(10):1470-6
pubmed: 17953482
J Virol. 2016 Nov 28;90(24):11247-11258
pubmed: 27707932
Emerg Infect Dis. 2006 Nov;12(11):1657-62
pubmed: 17283614
Lancet Infect Dis. 2007 Apr;7(4):257-65
pubmed: 17376383
J Infect Dis. 2013 Apr;207(7):1037-46
pubmed: 23372182
Lancet Infect Dis. 2012 Oct;12(10):744; author reply 744-5
pubmed: 23017359
PLoS Pathog. 2013 Mar;9(3):e1003205
pubmed: 23505369
J Hosp Infect. 2013 May;84(1):22-6
pubmed: 23498357
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1081-1086
pubmed: 29348203
Am J Epidemiol. 2008 Apr 1;167(7):775-85
pubmed: 18230677
J Infect Dis. 2012 Jan 1;205(1):35-43
pubmed: 22131338
Sci Transl Med. 2013 Sep 18;5(203):203ra126
pubmed: 24048524
Lancet Infect Dis. 2011 Nov;11(11):879-86
pubmed: 21798808
Cell Host Microbe. 2009 Sep 17;6(3):207-17
pubmed: 19664979
Lancet Respir Med. 2014 Jun;2(6):445-54
pubmed: 24717637

Auteurs

Jonathan S Nguyen-Van-Tam (JS)

Health Protection and Influenza Research Group, Division of Epidemiology and Public Heath, University of Nottingham School of Medicine, Nottingham, United Kingdom.

Ben Killingley (B)

Health Protection and Influenza Research Group, Division of Epidemiology and Public Heath, University of Nottingham School of Medicine, Nottingham, United Kingdom.

Joanne Enstone (J)

Health Protection and Influenza Research Group, Division of Epidemiology and Public Heath, University of Nottingham School of Medicine, Nottingham, United Kingdom.

Michael Hewitt (M)

Health Protection and Influenza Research Group, Division of Epidemiology and Public Heath, University of Nottingham School of Medicine, Nottingham, United Kingdom.

Jovan Pantelic (J)

University of Maryland School of Public Health, Maryland Institute for Applied Environmental Health, College Park, Maryland, United States of America.

Michael L Grantham (ML)

University of Maryland School of Public Health, Maryland Institute for Applied Environmental Health, College Park, Maryland, United States of America.

P Jacob Bueno de Mesquita (PJ)

University of Maryland School of Public Health, Maryland Institute for Applied Environmental Health, College Park, Maryland, United States of America.

Robert Lambkin-Williams (R)

hVIVO London, United Kingdom.

Anthony Gilbert (A)

hVIVO London, United Kingdom.

Alexander Mann (A)

hVIVO London, United Kingdom.

John Forni (J)

hVIVO London, United Kingdom.

Catherine J Noakes (CJ)

University of Leeds School of Civil Engineering, Leeds, United Kingdom.

Min Z Levine (MZ)

Centers for Disease Control and Prevention, Influenza Division, Atlanta, Georgia, United States of America.

LaShondra Berman (L)

Centers for Disease Control and Prevention, Influenza Division, Atlanta, Georgia, United States of America.

Stephen Lindstrom (S)

Centers for Disease Control and Prevention, Influenza Division, Atlanta, Georgia, United States of America.

Simon Cauchemez (S)

Imperial College London, MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, London, United Kingdom.

Werner Bischoff (W)

Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America.

Raymond Tellier (R)

McGill University, Dept of Medicine, Montreal, Canada.

Donald K Milton (DK)

University of Maryland School of Public Health, Maryland Institute for Applied Environmental Health, College Park, Maryland, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH